ABSTRACT
Vasoplegia describes a constellation of low vascular resistance and normal cardiac output. Vasoplegia is common after cardiac surgery in general and in heart transplant recipients more specifically and occurs in over one-half of all heart transplant recipients with a varying degree of severity. The pathophysiology of vasoplegia is multifactorial and associated with a cascade of inflammatory mediators. Routine treatment of vasoplegia is based on medical vasopressor therapy, but in severe cases this may be insufficient to maintain adequate blood pressure and does not address the underlying pathophysiology. We report a case of severe vasoplegic shock in a heart transplant recipient who was successfully managed with a multimodal therapy combination of methylene blue, immunoglobulins enriched with immunoglobulin M, cytokine adsorption, and broad-spectrum antibiotics. This represents a promising therapeutic approach for heart transplant patients with vasoplegia.
Subject(s)
Heart Transplantation , Methylene Blue , Vasoplegia , Humans , Heart Transplantation/adverse effects , Vasoplegia/drug therapy , Vasoplegia/etiology , Vasoplegia/physiopathology , Vasoplegia/diagnosis , Treatment Outcome , Combined Modality Therapy , Severity of Illness Index , Anti-Bacterial Agents/therapeutic use , Male , Cytokines , Middle Aged , Shock/physiopathology , Shock/etiology , Shock/diagnosis , Shock/therapy , Shock/drug therapyABSTRACT
This study aims to associate the incidence of postoperative vasoplegia and short-term survival to the implantation of various left ventricular assist devices differing in hemocompatibility and flow profiles. The overall incidence of vasoplegia was 25.3% (73/289 patients) and 30.3% (37/122), 25.0% (18/72), and 18.9% (18/95) in the axial flow (AXF), centrifugal flow (CF), and centrifugal flow with artificial pulse (CFAP) group, respectively. Vasoplegia was associated with longer intensive care (ICU) and hospital length of stay (LOS) and mortality. ICU and in-hospital LOS and 1-year mortality were the lowest in the CFAP group. Post hoc analysis resulted in a p-value of 0.43 between AXF and CF; 0.35 between CF and CFAP; and 0.06 between AXF and CFAP. Although there is a trend in diminished incidence of vasoplegia, pooled logistic regression using flow profile and variables that remained after feature selection showed that flow profile was not an independent predictor for postoperative vasoplegia.
Subject(s)
Heart-Assist Devices , Length of Stay , Prosthesis Design , Vasoplegia , Ventricular Function, Left , Humans , Vasoplegia/physiopathology , Vasoplegia/etiology , Vasoplegia/diagnosis , Male , Female , Middle Aged , Time Factors , Treatment Outcome , Incidence , Risk Factors , Adult , Aged , Heart Failure/physiopathology , Heart Failure/mortality , Heart Failure/diagnosis , Heart Failure/therapy , Prosthesis Implantation/instrumentation , Prosthesis Implantation/adverse effects , Prosthesis Implantation/mortality , Retrospective Studies , Hospital Mortality , Risk AssessmentABSTRACT
Vasoplegia observed post cardiopulmonary bypass (CPB) is associated with substantial morbidity, multiple organ failure and mortality. Circulating counts of hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPC) are potential markers of neo-vascularization and vascular repair. However, the significance of changes in the circulating levels of these progenitors in perioperative CPB, and their association with post-CPB vasoplegia, are currently unexplored. We enumerated HSC and EPC counts, via flow cytometry, at different time-points during CPB in 19 individuals who underwent elective cardiac surgery. These 19 individuals were categorized into two groups based on severity of post-operative vasoplegia, a clinically insignificant vasoplegic Group 1 (G1) and a clinically significant vasoplegic Group 2 (G2). Differential changes in progenitor cell counts during different stages of surgery were compared across these two groups. Machine-learning classifiers (logistic regression and gradient boosting) were employed to determine if differential changes in progenitor counts could aid the classification of individuals into these groups. Enumerating progenitor cells revealed an early and significant increase in the circulating counts of CD34+ and CD34+CD133+ hematopoietic stem cells (HSC) in G1 individuals, while these counts were attenuated in G2 individuals. Additionally, EPCs (CD34+VEGFR2+) were lower in G2 individuals compared to G1. Gradient boosting outperformed logistic regression in assessing the vasoplegia grouping based on the fold change in circulating CD 34+ levels. Our findings indicate that a lack of early response of CD34+ cells and CD34+CD133+ HSCs might serve as an early marker for development of clinically significant vasoplegia after CPB.
Subject(s)
Blood Cell Count , Cardiopulmonary Bypass/adverse effects , Endothelial Progenitor Cells , Hematopoietic Stem Cells , Vasoplegia/blood , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anthropometry , Comorbidity , Elective Surgical Procedures , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Intraoperative Period , Kinetics , Machine Learning , Male , Middle Aged , Pilot Projects , Postoperative Period , Severity of Illness Index , Vasoplegia/physiopathologyABSTRACT
Vasoplegic syndrome is a common occurrence following cardiothoracic surgery and is characterized as a high-output shock state with poor systemic vascular resistance. The pathophysiology is complex and includes dysregulation of vasodilatory and vasoconstrictive properties of smooth vascular muscle cells. Specific bypass machine and patient factors play key roles in occurrence. Research into treatment of this syndrome is limited and extrapolated primarily from that pertaining to septic shock, but is evolving with the expanded use of catecholamine-sparing agents. Recent reports demonstrate potential benefit in novel treatment options, but large clinical trials are needed to confirm.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Vasoplegia/drug therapy , Vasoplegia/physiopathology , Adrenal Cortex Hormones/therapeutic use , Angiotensin II/therapeutic use , Ascorbic Acid/therapeutic use , Cardiac Surgical Procedures/methods , Dopamine/therapeutic use , Enzyme Inhibitors/therapeutic use , Epinephrine/therapeutic use , Humans , Methylene Blue/therapeutic use , Norepinephrine/therapeutic use , Phenylephrine/therapeutic use , Sympathomimetics/therapeutic use , Vascular Resistance/drug effects , Vascular Resistance/physiology , Vasoconstrictor Agents/therapeutic use , Vasoplegia/etiology , Vasopressins/therapeutic useABSTRACT
BACKGROUND: Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and the resistance to vasopressors. However, the precise etiology remains unclear. The aim of the Vasoresponsiveness in patients with heart failure (VASOR) study is to objectify and characterize the altered vasoresponsiveness in patients with heart failure, before, during and after heart failure surgery and to identify the etiological factors involved. METHODS: This is a prospective, observational study conducted at Leiden University Medical Center. Patients with and patients without heart failure undergoing cardiac surgery on cardiopulmonary bypass are enrolled. The study is divided in two inclusion phases. During phase 1, 18 patients with and 18 patients without heart failure are enrolled. The vascular reactivity in response to a vasoconstrictor (phenylephrine) and a vasodilator (nitroglycerin) is assessed in vivo on different timepoints. The response to phenylephrine is assessed on t1 (before induction), t2 (before induction, after start of cardiotropic drugs and/or vasopressors), t3 (after induction), t4 (15 min after cessation of cardiopulmonary bypass) and t5 (1 day post-operatively). The response to nitroglycerin is assessed on t1 and t5. Furthermore, a sample of pre-pericardial fat tissue, containing resistance arteries, is collected intraoperatively. The ex vivo vascular reactivity is assessed by constructing concentrations response curves to various vasoactive substances using isolated resistance arteries. Next, expression of signaling proteins and receptors is assessed using immunohistochemistry and mRNA analysis. Furthermore, the groups are compared with respect to levels of organic compounds that can influence the cardiovascular system (e.g. copeptin, (nor)epinephrine, ANP, BNP, NTproBNP, angiotensin II, cortisol, aldosterone, renin and VMA levels). During inclusion phase 2, only the ex vivo vascular reactivity test is performed in patients with (N = 12) and without heart failure (N = 12). DISCUSSION: Understanding the difference in vascular responsiveness between patients with and without heart failure in detail, might yield therapeutic options or development of preventive strategies for vasoplegia, leading to safer surgical interventions and improvement in outcome. TRIAL REGISTRATION: The Netherlands Trial Register (NTR), NTR5647. Registered 26 January 2016.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Heart Failure/surgery , Postoperative Complications/etiology , Vasodilation/physiology , Vasoplegia/etiology , Female , Heart Failure/physiopathology , Humans , Male , Middle Aged , Postoperative Complications/physiopathology , Prospective Studies , Vasoplegia/physiopathology , Vasoplegia/prevention & controlSubject(s)
Angiotensin II/therapeutic use , Cardiopulmonary Bypass/adverse effects , Hemodynamics/physiology , Postoperative Complications , Vasoplegia/drug therapy , Adult , Hemodynamics/drug effects , Humans , Male , Middle Aged , Vasoconstrictor Agents/therapeutic use , Vasoplegia/etiology , Vasoplegia/physiopathologyABSTRACT
A 67-year-old male underwent general anesthesia for left atrial appendage occlusion. During the procedure, the patient developed catecholamine refractory hypotension requiring the administration of several vasopressin boluses to maintain adequate perfusion pressure. At the conclusion of the procedure, mild venous bleeding necessitated the administration of protamine. This led to a further decrease in the patient's blood pressure. Tamponade and continued volume loss were quickly ruled out leading to a diagnosis of vasoplegia syndrome (VS). The patient was appropriately treated with a vasopressin infusion with normalization of blood pressure and no significant morbidity or adverse outcome. With the use of general anesthesia during structural heart interventions on the rapid rise, we discuss the two common causes for vasoplegia along with evidence-based treatments and possible prevention strategies.
Subject(s)
Anesthesia, General/adverse effects , Atrial Fibrillation/therapy , Blood Pressure , Cardiac Catheterization , Vasoplegia/etiology , Aged , Atrial Appendage/physiopathology , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Atrial Function, Left , Blood Pressure/drug effects , Cardiac Catheterization/instrumentation , Humans , Male , Risk Factors , Treatment Outcome , Vasoconstrictor Agents/administration & dosage , Vasoplegia/diagnosis , Vasoplegia/drug therapy , Vasoplegia/physiopathology , Vasopressins/administration & dosageABSTRACT
Vasoplegic syndrome is a state of vasopressor resistant systemic vasodilation in the presence of a normal cardiac output. Its definition, pathophysiology, risk factors, diagnosis and therapeutic approach will be reviewed in this paper. It occurs frequently during cardiac surgery and is associated with high morbidity and mortality. A search in the LILACS, MEDLINE, and GOOGLE SCHOLAR databases was conducted to find the most relevant papers during the last 18 years. Prompt identification and diagnosis of patients at risk must be undertaken in order to implement an optimal therapeutic approach. This latter includes early treatment with vasopressors with different mechanisms of action.
Subject(s)
Cardiac Surgical Procedures , Intraoperative Complications , Vasoplegia , Algorithms , Humans , Intraoperative Complications/diagnosis , Intraoperative Complications/physiopathology , Intraoperative Complications/therapy , Risk Factors , Vasoplegia/diagnosis , Vasoplegia/physiopathology , Vasoplegia/therapyABSTRACT
OBJECTIVE: To compare the efficacy of methylene blue with combination therapy with hydroxocobalamin in patients experiencing vasoplegic syndrome after cardiac surgery. DESIGN: Retrospective cohort study. SETTING: Tertiary medical center. PARTICIPANTS: Patients who received methylene blue with or without hydroxocobalamin for refractory vasoplegic syndrome rescue therapy. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 0.the ability to maintain mean arterial pressure (MAP) >60 mmHg beyond 1hour after study drug administration. Other pertinent outcomes included MAP at hours 6, 12, and 24 post-administration; both raw and proportional changes of vasopressor doses from baseline at hours 1, 6, 12, and 24 post-administration; and change in pulmonary artery catheter hemodynamics. Overall, 28 doses were administered in 14 patients in the monotherapy group and 17 doses (10 methylene blue, 7 hydroxocobalamin) were administered in 6 patients in the combination therapy group. There were no differences in ability to maintain MAP at 1hour, with 71% of the monotherapy and 82% of combination therapy patients meeting MAP goals (pâ¯=â¯0.49). Pairwise comparisons demonstrated vasopressor reductions at 6, 12, and 24hours in both groups, but only significant reductions at 1hour were observed in the combination therapy group (-0.06 µg/kg/min; pâ¯=â¯0.003) but not in the monotherapy group (-0.015 µg/kg/min; pâ¯=â¯0.14). CONCLUSION: This is the first study to compare methylene blue monotherapy with combination therapy, which suggests there may be an advantage to combination therapy. Further characterization of ideal dosing, timing, and agent selection should be investigated on a larger scale format.
Subject(s)
Hydroxocobalamin/administration & dosage , Methylene Blue/administration & dosage , Vasoconstrictor Agents/administration & dosage , Vasoplegia/drug therapy , Vasoplegia/physiopathology , Aged , Aged, 80 and over , Cohort Studies , Drug Therapy, Combination , Enzyme Inhibitors/administration & dosage , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Vasoplegia/diagnosis , Vitamin B Complex/administration & dosageABSTRACT
Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.
Subject(s)
Cardiopulmonary Bypass/adverse effects , Hemodynamics/drug effects , Hydroxocobalamin/therapeutic use , Hypotension/drug therapy , Vasoconstrictor Agents/therapeutic use , Vasoplegia/drug therapy , Vitamin B Complex/therapeutic use , Aged , Female , Humans , Hydroxocobalamin/adverse effects , Hypotension/diagnosis , Hypotension/epidemiology , Hypotension/physiopathology , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Vasoconstrictor Agents/adverse effects , Vasoplegia/diagnosis , Vasoplegia/etiology , Vasoplegia/physiopathology , Vitamin B Complex/adverse effectsABSTRACT
BACKGROUND: Vasoplegia is a severe complication that can develop after surgical procedures for heart failure. The current study evaluated the effect of vasoplegia on survival, cardiac function, and renal function 2 years after surgical left ventricular restoration (SVR). METHODS: Heart failure patients with a left ventricular ejection fraction (LVEF) of 0.35 or less who underwent SVR in 2006 to 2014 were included. Vasoplegia was defined as the continuous need of vasopressors (norepinephrine ≥0.2 µg · kg-1 · min-1 or terlipressin [any dose], or both) combined with a cardiac index of 2.2 L · min-1 · m-2 or higher for at least 12 consecutive hours, starting within the first 3 days postoperatively. The effect of vasoplegia on mortality, New York Heart Association Functional Classification, LVEF, and creatinine clearance was assessed up to 2 years of follow-up. RESULTS: SVR was performed in 113 patients (80% men), aged 62 ± 10 years, and with an LVEF of 0.25 ± 0.06. Postoperative vasoplegia developed in 23%. Survival was lower in patients with vasoplegia compared with patients without vasoplegia at 6 months (62% vs 90%, p = 0.001) and at 2 years (50% versus 84%, p < 0.001). At the 2-year follow-up, New York Heart Association class and LVEF had improved and were similar in both groups (respectively, p = 0.319 and p = 0.444). Creatinine clearance was lower in patients with vasoplegia compared with patients without vasoplegia 2 years postoperatively (p < 0.001), even after correcting for baseline creatinine clearance (p = 0.009). CONCLUSIONS: Vasoplegia after SVR is associated with decreased survival. Despite an improved and similar cardiac function, renal function was compromised in vasoplegic patients at the 2-year follow-up.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Heart Failure/surgery , Hospital Mortality/trends , Vasoplegia/etiology , Vasoplegia/mortality , Ventricular Dysfunction, Left/surgery , Academic Medical Centers , Aged , Cardiac Surgical Procedures/methods , Cohort Studies , Female , Follow-Up Studies , Heart Failure/diagnostic imaging , Heart Failure/mortality , Humans , Male , Middle Aged , Netherlands , Retrospective Studies , Risk Assessment , Stroke Volume , Survival Analysis , Time Factors , Treatment Outcome , Vasoplegia/physiopathology , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/mortalityABSTRACT
BACKGROUND: Dynamic arterial elastance (Eadyn) has been proposed as an indicator of vascular tone that predicts the decrease in arterial pressure in response to changes in norepinephrine (NE). The purpose of this study was to determine whether Eadyn measured by uncalibrated pulse contour analysis (UPCA) can predict a decrease in arterial pressure when the NE dosage is decreased. METHODS: We conducted a prospective study in a university hospital intensive care unit. Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the NE dosage were included. Haemodynamic and UPCA (VolumeView and FloTrac; Edwards Lifesciences, Irvine, CA, USA) values were obtained before and after decreasing the NE dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP). RESULTS: Of 35 patients included, 11 (31%) were pressure responders with a median decrease of 13%. Eadyn was correlated to systolic arterial pressure (SAP) (r=0.255; P=0.033), diastolic arterial pressure (r=0.271; P=0.024), MAP (r=0.310; P=0.009), heart rate (r=0.543; P=0.0001), and transthoracic echography cardiac output (r=0.264; P=0.024). Baseline Eadyn was correlated with MAP changes (r=0.394; P=0.019) and SAP changes (r=0.431; P=0.009). Eadyn predicted the decrease in arterial pressure with an area under the receiver-operating-characteristic curve of 0.84 (95% confidence interval: 0.70-0.97). The best cut-off was 0.90. CONCLUSIONS: The present study confirms the ability of Eadyn measured by UPCA to predict an arterial pressure response to a decrease in NE. Eadyn may constitute an easy-to-use functional approach to arterial tone assessment regardless of the monitor used to measure its determinant. CLINICAL TRIAL REGISTRATION: DRCIT95.
Subject(s)
Arterial Pressure/drug effects , Norepinephrine/administration & dosage , Pulse Wave Analysis/methods , Vasoconstrictor Agents/administration & dosage , Vasoplegia/drug therapy , Aged , Aged, 80 and over , Arterial Pressure/physiology , Critical Care/methods , Dose-Response Relationship, Drug , Elasticity/drug effects , Elasticity/physiology , Female , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Male , Middle Aged , Monitoring, Physiologic/methods , Norepinephrine/pharmacology , Prospective Studies , Vasoconstrictor Agents/pharmacology , Vasoplegia/physiopathologyABSTRACT
Vasoplegia is the syndrome of pathological low systemic vascular resistance, the dominant clinical feature of which is reduced blood pressure in the presence of a normal or raised cardiac output. The vasoplegic syndrome is encountered in many clinical scenarios, including septic shock, post-cardiac bypass and after surgery, burns and trauma, but despite this, uniform clinical definitions are lacking, which renders translational research in this area challenging. We discuss the role of vasoplegia in these contexts and the criteria that are used to describe it are discussed. Intrinsic processes which may drive vasoplegia, such as nitric oxide, prostanoids, endothelin-1, hydrogen sulphide and reactive oxygen species production, are reviewed and potential for therapeutic intervention explored. Extrinsic drivers, including those mediated by glucocorticoid, catecholamine and vasopressin responsiveness of the blood vessels, are also discussed. The optimum balance between maintaining adequate systemic vascular resistance against the potentially deleterious effects of treatment with catecholamines is as yet unclear, but development of novel vasoactive agents may facilitate greater understanding of the role of the differing pathways in the development of vasoplegia. In turn, this may provide insights into the best way to care for patients with this common, multifactorial condition.
Subject(s)
Anaphylaxis/classification , Anaphylaxis/physiopathology , Shock, Septic/classification , Shock, Septic/physiopathology , Free Radicals/analysis , Free Radicals/blood , Humans , Hydrogen Sulfide/analysis , Hydrogen Sulfide/blood , Prostaglandins/analysis , Prostaglandins/blood , Vascular Resistance/physiology , Vasoplegia/complications , Vasoplegia/physiopathologyABSTRACT
BACKGROUND: Vasoplegia is associated with adverse outcomes following cardiac surgery; however, its impact following left ventricular assist device implantation is largely unexplored. METHODS AND RESULTS: In 252 consecutive patients receiving a left ventricular assist device, vasoplegia was defined as the occurrence of normal cardiac function and index but with the need for intravenous vasopressors within 48 hours following surgery for >24 hours to maintain a mean arterial pressure >70 mm Hg. We further categorized vasoplegia as none; mild, requiring 1 vasopressor (vasopressin, norepinephrine, or high-dose epinephrine [>5 µg/min]); or moderate to severe, requiring ≥2 vasopressors. Predictors of vasoplegia severity were determined using a cumulative logit (ordinal logistic regression) model, and 1-year mortality was evaluated using competing-risks survival analysis. In total, 67 (26.6%) patients developed mild vasoplegia and 57 (22.6%) developed moderate to severe vasoplegia. The multivariable model for vasoplegia severity utilized preoperative Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time, which yielded an area under the curve of 0.76. Although no significant differences were noted in stroke or pump thrombosis rates (P=0.87 and P=0.66, respectively), respiratory failure and major bleeding increased with vasoplegia severity (P<0.01). Those with moderate to severe vasoplegia had a significantly higher risk of mortality than those without vasoplegia (adjusted hazard ratio: 2.12; 95% confidence interval, 1.08-4.18; P=0.03). CONCLUSIONS: Vasoplegia is predictive of unfavorable outcomes, including mortality. Risk factors for future research include preoperative INTERMACS profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time.
Subject(s)
Arterial Pressure , Heart Failure/therapy , Heart-Assist Devices , Prosthesis Implantation/adverse effects , Prosthesis Implantation/instrumentation , Vasoplegia/etiology , Ventricular Function, Left , Aged , Arterial Pressure/drug effects , Cardiopulmonary Bypass , Central Venous Pressure , Female , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Male , Middle Aged , Prosthesis Design , Prosthesis Implantation/mortality , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome , Vasoconstrictor Agents/therapeutic use , Vasoplegia/drug therapy , Vasoplegia/mortality , Vasoplegia/physiopathologyABSTRACT
OBJECTIVES: Vasoplegic syndrome (VS) affects up to 30% of cardiac surgery patients. Onset of VS may be associated with overproduction of nitric oxide (NO). The response of the brachial artery to NO can be assessed using flow-mediated vasodilation (FMD). The aim of this study was to assess brachial artery diameter and FMD response immediately after cardiac surgery. DESIGN: Prospective, observational study. SETTING: Single-center study in a tertiary teaching hospital. PATIENTS: Patients older than 18 years undergoing elective cardiac surgery with cardiopulmonary bypass who provided informed consent. INTERVENTIONS: Brachial artery diameter and FMD response were measured before cardiac surgery and just after surgery on admission to the intensive care unit. Patients were screened for VS for the following 48 hours. RESULTS: Eleven (39%) of the 28 patients included in the study developed VS. Brachial artery diameter and FMD differed between VS and non-VS patients. On intensive care unit admission, mean (± standard deviation) brachial artery diameter was greater in VS patients than in non-VS patients (3.9 ± 0.7 mm v 3.0 ± 0.8 mm, respectively; p = 0.002). Similarly, the FMD response after surgery was greater in VS patients than in non-VS patients (42% ± 8% v 31% ± 1%, respectively; p = 0.014). Brachial artery diameter and FMD response after surgery were both predictive of VS, with an area under the curve (95% confidence interval) of 0.850 (0.705-0.995) (p = 0.002) and 0.755 (0.56-0.95) (p = 0.047), respectively. CONCLUSION: Cardiac surgery with cardiopulmonary bypass appears to alter the NO-mediated endothelial vasomotor response.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Endothelium, Vascular/physiopathology , Postoperative Complications , Vasodilation/physiology , Vasoplegia/etiology , Aged , Female , Follow-Up Studies , France/epidemiology , Humans , Incidence , Male , Middle Aged , Prospective Studies , Survival Rate/trends , Vascular Resistance/physiology , Vasoplegia/epidemiology , Vasoplegia/physiopathologyABSTRACT
Vasoplegia is a ubiquitous phenomenon in all advanced shock states, including septic, cardiogenic, hemorrhagic, and anaphylactic shock. Its pathophysiology is complex, involving various mechanisms in vascular smooth muscle cells such as G protein-coupled receptor desensitization (adrenoceptors, vasopressin 1 receptors, angiotensin type 1 receptors), alteration of second messenger pathways, critical illness-related corticosteroid insufficiency, and increased production of nitric oxide. This review, based on a critical appraisal of the literature, discusses the main current treatments and future approaches. Our improved understanding of these mechanisms is progressively changing our therapeutic approach to vasoplegia from a standardized to a personalized multimodal treatment with the prescription of several vasopressors. While norepinephrine is confirmed as first line therapy for the treatment of vasoplegia, the latest Surviving Sepsis Campaign guidelines also consider that the best therapeutic management of vascular hyporesponsiveness to vasopressors could be a combination of multiple vasopressors, including norepinephrine and early prescription of vasopressin. This new approach is seemingly justified by the need to limit adrenoceptor desensitization as well as sympathetic overactivation given its subsequent deleterious impacts on hemodynamics and inflammation. Finally, based on new pathophysiological data, two potential drugs, selepressin and angiotensin II, are currently being evaluated.
Subject(s)
Adrenal Cortex Hormones/metabolism , Vasoconstrictor Agents/pharmacokinetics , Vasoplegia/drug therapy , Adrenal Cortex Hormones/therapeutic use , Adrenergic alpha-Agonists/pharmacokinetics , Adrenergic alpha-Agonists/therapeutic use , Humans , Norepinephrine/metabolism , Norepinephrine/therapeutic use , Shock/complications , Shock/drug therapy , Shock/physiopathology , Vasoconstrictor Agents/pharmacology , Vasoconstrictor Agents/therapeutic use , Vasoplegia/etiology , Vasoplegia/physiopathologyABSTRACT
Vasoplegia occurs in up to 16% of patients who undergo heart transplantation (HT) and is associated with significant morbidity and mortality. We present a case of a 61-year-old man with ischemic cardiomyopathy receiving sacubitril/valsartan (Entresto; Novartis, Cambridge, MA) who developed profound hypotension after HT. He was treated with intravenous methylene blue and high-dose vasopressors, but developed acute kidney injury requiring dialysis and a prolonged stay in the intensive care unit. This case supports a potent vasodilatory effect of sacubitril/valsartan, and if confirmed by other studies, might warrant consideration for withholding treatment while awaiting HT, particularly in patients with risk factors for vasoplegia.
Subject(s)
Aminobutyrates/adverse effects , Cardiomyopathies/surgery , Heart Transplantation/adverse effects , Tetrazoles/adverse effects , Valsartan/adverse effects , Vasoplegia/chemically induced , Aminobutyrates/therapeutic use , Biphenyl Compounds , Cardiomyopathies/diagnosis , Drug Combinations , Follow-Up Studies , Heart Transplantation/methods , Humans , Length of Stay , Male , Middle Aged , Postoperative Care/methods , Risk Assessment , Severity of Illness Index , Tetrazoles/therapeutic use , Treatment Outcome , Valsartan/therapeutic use , Vasoplegia/physiopathology , Vasoplegia/therapyABSTRACT
Sepsis is one of the most frequent causes of death among patients in intensive care units. Many therapeutic strategies have been assessed without the desired success rates. A key risk factor for death is hypotension due to vasodilatation with vascular hyposensitivity. However, the pathways underlying this process remain unclear. Endotoxemia induces inflammatory mediators, and this is followed by vasoplegia and decreased cardiac contractility. Although inhibition of these mediators diminishes mortality rates in animal models, this phenomenon has not been confirmed in humans. Downregulation of vasoconstrictive receptors such as angiotensin receptors, adrenergic and vasopressin receptors is seen in sepsis, which is associated with a hyporesponsiveness to vasoconstrictive mediators. Animal studies have verified that receptor downregulation is linked to the above-mentioned inflammatory mediators. Anti-inflammatory therapy with glucocorticoids reportedly improves responsiveness to catecholamines with higher survival in rats, although this has not been shown to be clinically significant in humans. Hence, there is an urgent need for in-depth studies investigating the underlying mechanisms of vasoplegia to allow for development of effective therapeutic strategies for the treatment of sepsis.
Subject(s)
Shock, Septic/complications , Vasoplegia/complications , Animals , Humans , Inflammation Mediators/metabolism , Shock, Septic/physiopathology , Vasoconstriction , Vasoplegia/physiopathologyABSTRACT
OBJECTIVE: The aim of this study was to analyze risk factors and outcomes of vasoplegia after cardiac surgery based on our experience with almost 2000 cardiac operations performed at our institution. METHODS: We retrospectively analyzed patients who underwent cardiac surgery with cardiopulmonary bypass (CPB) between 2011 and 2013. Data were available for a total of 1992 patients. We defined vasoplegia as hypotension with persistently low systemic vascular resistance (<800 dyn/s/cm) and preserved Cardiac Index (>2.5). RESULTS: The rate of vasoplegia in our cohort was 20.3% (n = 405). The incidences of mild, moderate, and severe vasoplegia were 13.2, 5.7, and 1.5%, respectively. Factors that increased risk of vasoplegia included valve operations, heart transplants, dialysis-dependent renal failure, age >65, diuretic therapy, and recent myocardial infarction. B blocker therapy was protective against vasoplegia. CONCLUSION: Vasoplegic syndrome is still a frequently occurring adverse event following cardiac surgery. In high risk patients for vasoplegia, it may be sensible to proceed with preoperative volume loading (instead of diuresis), initiation of low dose vasopressin therapy if needed, and attempting to up titrate beta-blocker therapy.